On March 14, 2023 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 14-19, 2023, in Orlando, FL (Press release, ORIC Pharmaceuticals, MAR 14, 2023, View Source [SID1234628656]). The presentations will highlight:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

preclinical biomarker results for ORIC-944, a potent and selective allosteric inhibitor of PRC2 currently in Phase 1 for patients with metastatic prostate cancer; and
preclinical data from ORIC’s selective PLK4 inhibitor discovery program
Details of the presentations are as follows:

Title: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacokinetics, Pharmacodynamics, and Molecular
Pharmacology
Session Date & Time: Monday, April 17, 2023, 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 18
Abstract Number: 2791